These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 31858913)

  • 1. Cotrimoxazole Prophylaxis is Not Associated with a Higher Occurrence of Atazanavir Treatment Failure: Analysis of Worldwide Pharmacovigilance Data.
    Basilua JM; Pochart P
    Infect Disord Drug Targets; 2021; 21(1):55-59. PubMed ID: 31858913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant Use of Cotrimoxazole and Atazanavir in HIV-infected Patients: A Therapeutic Drug Monitoring and Pharmacovigilance Based Dual Approach.
    Joe MB; Roland L; Laurent C; Patrick LM; Sawoo O; Gaston TL; Bruno E; Gilles P; Philippe P
    Curr Clin Pharmacol; 2019; 14(3):214-223. PubMed ID: 30961507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of HIV treatment failure in Africa using the WHO Pharmacovigilance data.
    Miantezila Basilua J; Mesia Kahunu G; Pochart P; Tona Lutete G
    Trop Med Int Health; 2021 May; 26(5):530-534. PubMed ID: 33529447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
    Sevinsky H; Zaru L; Wang R; Xu X; Pikora C; Correll TA; Eley T
    Pediatr Infect Dis J; 2018 Jun; 37(6):e157-e165. PubMed ID: 29206748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
    Giacomelli A; Oreni L; Franzetti M; Di Cristo V; Colella E; Ridolfo AL; Galli M; Rusconi S
    Antiviral Res; 2016 May; 129():52-57. PubMed ID: 26902109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
    d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
    Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher Atazanavir Plasma Exposure in Rats is Associated with Gut Microbiota Changes Induced by Cotrimoxazole.
    Basilua JM; Sawoo O; Mangin I; Dossou-Yovo F; Boussard A; Chevillard L; Lutete GT; Eto B; Peytavin G; Pochart P
    Curr Drug Metab; 2019; 20(11):898-906. PubMed ID: 31702484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
    Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
    HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
    Colella E; Cattaneo D; Galli L; Baldelli S; Clementi E; Galli M; Lazzarin A; Castagna A; Rusconi S; Spagnuolo V
    New Microbiol; 2018 Apr; 41(2):106-111. PubMed ID: 29498742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.
    Ferretti F; Bigoloni A; Passeri L; Galli L; Longo V; Gerevini S; Spagnuolo V; Gisslen M; Zetterberg H; Fuchs D; Cattaneo D; Caramatti G; Lazzarin A; Cinque P; Castagna A
    Medicine (Baltimore); 2016 Jul; 95(28):e4144. PubMed ID: 27428202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
    Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
    J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
    Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
    J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
    Keiser PH; Nassar N
    Int J STD AIDS; 2008 Aug; 19(8):561-2. PubMed ID: 18663047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women.
    Lê MP; Mandelbrot L; Descamps D; Soulié C; Ichou H; Bourgeois-Moine A; Damond F; Lariven S; Valantin MA; Landman R; Faucher P; Tubiana R; Duro D; Meier F; Legac S; Bourse P; Mortier E; Dommergues M; Calvez V; Matheron S; Peytavin G
    Antivir Ther; 2015; 20(5):507-13. PubMed ID: 25599649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
    Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
    Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
    Wohl DA; Bhatti L; Small CB; Edelstein H; Zhao HH; Margolis DA; DeJesus E; Weinberg WG; Ross LL; Shaefer MS
    HIV Med; 2016 Feb; 17(2):106-17. PubMed ID: 26176344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
    Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
    HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
    Teófilo E; Rocha-Pereira N; Kuhlmann B; Antela A; Knechten H; Santos J; Jiménez-Expósito MJ;
    HIV Clin Trials; 2016 Feb; 17(1):17-28. PubMed ID: 26899539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.